Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages 757-770

  Das, Kakoli ^a,b   Lorena, Pia D N ^b   Ng, Lai Kuan ^b   Lim, Diana ^b   Shen, Liang ^b   Siow, Woei Yun ^c   Teh, Ming ^b   Reichardt, Juergen K V ^d   Salto Tellez, Manuel ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANGIOGENIC FACTOR; DUTASTERIDE; ENDOTHELIN; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CARCINOGENESIS; CELL STRAIN; CELL STRAIN LNCAP; CELL STRAIN PC 3; CELL STRAIN RWPE 1; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; TRANSURETHRAL RESECTION; UPREGULATION; WESTERN BLOTTING;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; 5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; AZASTEROIDS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL NUCLEUS; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FINASTERIDE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; ISOENZYMES; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956366809     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0022     Document Type: Article

References (48)

1. Aslan G, Cimen S, Yorukoglu K, Tuna B, Sonmez D, Mungan U & Celebi I 2005 Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathology, Research and Practice 201 593-598. (Pubitemid 41363954)
2. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR & Harris AL 2005 The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clinical Cancer Research 11 7658-7663.
3. Bonkhoff H, Stein U, Aumuller G & Remberger K 1996 Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29 261-267. (Pubitemid 26365292)
4. Bruchovsky N, Rennie PS, Batzold FH, Goldenberg SL, Fletcher T & McLoughlin MG 1988 Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. Journal of Clinical Endocrinology and Metabolism 67 806-816.
5. Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA & Eble JN 2004 Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Research 24 2135-2140. (Pubitemid 39166287)
6. Das K, Cheah PY, Lim PL, Zain YB, Stephanie FC, Zhao Y, Cheng C & Lau W 2008a Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer. Cancer Letters 268 340-347.
7. Das K, Mohd Omar MF, Ong CW, Bin Abdul Rashid S, Peh BK, Putti TC, Tan PH, Chia KS, Teh M & Shah N 2008b TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. Pathology 40 441-449.
8. Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, van Wijnen AJ & Salto-Tellez M 2009 Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. European Journal of Cancer 45 2239-2248.
9. Derynck R, Akhurst RJ & Balmain A 2001 TGF-beta signaling in tumor suppression and cancer progression. Nature Genetics 29 117-129. (Pubitemid 32952643)
10. Ellis WJ & Isaacs JT 1985 Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Cancer Research 45 6041-6050.
11. Enderle-Schmitt U, Volck-Badouin E, Schmitt J & Aumuller G 1986 Functional characteristics of nuclear 5 alpha-reductase from rat ventral prostate. Journal of Steroid Biochemistry 25 209-217.
12. Ferrara N, Houck K, Jakeman L & Leung DW 1992 Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Reviews 13 18-32.
13. Folkman J 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1 27-31.
14. Gelmann EP 2002 Molecular biology of the androgen receptor. Journal of Clinical Oncology 20 3001-3015.
15. Gustafsson JA & Pousette A 1974 Properties of nuclear 5 alpha-reductase in rat liver. Biochemistry 13 875-881.
16. Habib FK, Ross M, Bayne CW, Bollina P, Grigor K & Chapman K 2003 The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clinical Cancer Research 9 1815-1819. (Pubitemid 36554609)
17. Hanahan D & Weinberg RA 2000 The hallmarks of cancer. Cell 100 57-70.
18. Joseph IB, Nelson JB, Denmeade SR & Isaacs JT 1997 Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clinical Cancer Research 3 2507-2511. (Pubitemid 28133175)
19. Karkkainen MJ & Petrova TV 2000 Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19 5598-5605.
20. Lachgar S, Charveron M, Sarraute J, Mourard M, Gall Y & Bonafe JL 1999 In vitro main pathways of steroid action in cultured hair follicle cells: vascular approach. Journal of Investigative Dermatology. Symposium Proceedings 4 290-295.
21. Lamb JC, Levy MA, Johnson RK & Isaacs JT 1992 Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. Prostate 21 15-34.
22. Lazier CB, Thomas LN, Douglas RC, Vessey JP & Rittmaster RS 2004 Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 58 130-144.
23. Leung DW, Cachianes G, Kuang WJ, Goeddel DV & Ferrara N 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 1306-1309. (Pubitemid 20066716)
24. Loges S, Mazzone M, Hohensinner P & Carmeliet P 2009 Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15 167-170.
25. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE & Reichardt JK 1999 Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354 975-978.
26. Moses HL, Yang EY & Pietenpol JA 1990 TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63 245-247.
27. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S & Yamada S 2005 In situ androgen producing enzymes in human prostate cancer. Endocrine-Related Cancer 12 101-107.
28. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D & Casanovas O 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 220-231.
29. Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB & Fracchia JA 2003 The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. Journal of Urology 169 20-23. (Pubitemid 35461539)
30. Pearce CL, Van Den Berg DJ, Makridakis N, Reichardt JK, Ross RK, Pike MC, Kolonel LN & Henderson BE 2008 No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Human Molecular Genetics 17 2456-2461.
31. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O & Alitalo K 1994 Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. Journal of Biological Chemistry 269 6271-6274.
32. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC & Ross RK 1995 Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Research 55 3973-3975.
33. Rittmaster RS, Fleshner NE & Thompson IM 2009 Pharmacological approaches to reducing the risk of prostate cancer. European Urology 55 1064-1073.
34. Russell DW & Wilson JD 1994 Steroid 5 alpha-reductase: two genes/two enzymes. Annual Review of Biochemistry 63 25-61. (Pubitemid 2109098)
35. Salto-Tellez M, Nga ME, Han HC, Wong AS, Lee CK, Anuar D, Ng SS, Ho M, Wee A & Chan YH 2007 Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. British Journal of Cancer 96 776-782.
36. Schmidt LJ, Murillo H & Tindall DJ 2004 Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. Journal of Andrology 25 944-953. (Pubitemid 39425600)
37. Sobin LH & Fleming ID 1997 TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80 1803-1804.
38. Thigpen AE & Russell DW 1992 Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. Journal of Biological Chemistry 267 8577-8583.
39. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD & Russell DW 1993 Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. Journal of Clinical Investigation 92 903-910.
40. Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS & Lazier CB 2003 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. Journal of Urology 170 2019-2025.
41. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP & Rittmaster RS 2005 Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63 231-239. (Pubitemid 40571057)
42. Titus MA, Gregory CW, Ford OH III, Schell MJ, Maygarden SJ & Mohler JL 2005 Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clinical Cancer Research 11 4365-4371. (Pubitemid 40825625)
43. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T & Higashino K 1992 Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochimica et Biophysica Acta 1137 189-196.
44. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y & Nakagawa H 2008 Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Science 99 81-86. (Pubitemid 350239034)
45. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T & Kodama T 2008 Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. Journal of Clinical Pathology 61 448-454.
46. Xu Y, Dalrymple SL, Becker RE, Denmeade SR & Isaacs JT 2006 Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clinical Cancer Research 12 4072-4079. (Pubitemid 44078095)
47. Zhang D, Salto-Tellez M, Putti TC, Do E & Koay ES 2003 Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Modern Pathology 16 79-84. (Pubitemid 36152690)
48. Zhu ML & Kyprianou N 2008 Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocrine-Related Cancer 15 841-849.